← back to search

Sarah P. Psutka

Southwestern Medical Center · US
Area of research
Surgery · Pulmonary and Respiratory Medicine
Research interest
Research focused on Bladder cancer and Sarcopenia, with related work in Epidemiology, Renal cell carcinoma, Incidence (geometry). Notable publications include 'Epidemiology of Renal Cell Carcinoma: 2022 Update', 'Epidemiology, Screening, and Prevention of Bladder Cancer', and 'Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline'.
h-index
citations
1,799
works
25
NIH funding
primary concept
email

Recent publications

Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer
Urologic Oncology Seminars and Original Investigations 2025cited by 20position: middledoi
End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer
Journal of Clinical Oncology 2025cited by 11position: middledoi
Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial
European Urology 2025cited by 9position: middledoi
TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial
The Lancet Oncology 2025cited by 8position: lastdoi
Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results
Journal of Clinical Oncology 2025cited by 5position: lastdoi
The Financial Burden of Localized and Metastatic Bladder Cancer
European Urology 2024cited by 62position: middledoi
LBA84 TAR-200 plus cetrelimab (CET) or CET alone as neoadjuvant therapy in patients (pts) with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy (NAC): Interim analysis of SunRISe-4 (SR-4)
Annals of Oncology 2024cited by 9position: lastdoi
The impact of single-port robotic surgery: a survey among urology residents and fellows in the United States
Journal of Robotic Surgery 2024cited by 6position: middledoi
Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline
The Journal of Urology 2023cited by 183position: middledoi
Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy
The Oncologist 2023cited by 19position: middledoi
Prognostic Significance of Grade Discrepancy Between Primary Tumor and Venous Thrombus in Nonmetastatic Clear-cell Renal Cell Carcinoma: Analysis of the REMEMBER Registry and Implications for Adjuvant Therapy
European Urology Oncology 2023cited by 14position: middledoi
Imaging Techniques to Determine Degree of Sarcopenia and Systemic Inflammation in Advanced Renal Cell Carcinoma
Current Urology Reports 2023cited by 11position: lastdoi
Low Skeletal Muscle as a Risk Factor for Worse Survival in Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus
Clinical Genitourinary Cancer 2023cited by 9position: middledoi
Epidemiology of Renal Cell Carcinoma: 2022 Update
European Urology 2022cited by 736position: lastdoi
Epidemiology, Screening, and Prevention of Bladder Cancer
European Urology Oncology 2022cited by 325position: middledoi
Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group
European Urology Oncology 2022cited by 85position: middledoi
Sarcopenia and systemic inflammation are associated with decreased survival after cytoreductive nephrectomy for metastatic renal cell carcinoma
Cancer 2022cited by 26position: middledoi
Prognostic Value of Sarcopenia and Albumin in the Surgical Management of Localized Renal Cell Carcinoma
Urologic Oncology Seminars and Original Investigations 2022cited by 14position: middledoi
Ablative Therapies for Localized Primary Renal Cell Carcinoma
Société Internationale d’Urologie Journal 2022cited by 13position: middledoi
Sarcopenia and modified Glasgow Prognostic Score predict postsurgical outcomes in localized renal cell carcinoma
Cancer 2021cited by 40position: middledoi
Segmentation and Linear Measurement for Body Composition Analysis using Slice-O-Matic and Horos
Journal of Visualized Experiments 2021cited by 22position: middledoi
MRI quantitation of abdominal skeletal muscle correlates with CT-based analysis: implications for sarcopenia measurement
Applied Physiology Nutrition and Metabolism 2019cited by 39position: middledoi
Staging the Host: Personalizing Risk Assessment for Radical Cystectomy Patients
European Urology Oncology 2018cited by 65position: firstdoi
Role of metastasis‐directed treatment in kidney cancer
Cancer 2018cited by 52position: firstdoi
Urology Residents' Experience and Attitude Toward Surgical Simulation: Presenting our 4-Year Experience With a Multi-institutional, Multi-modality Simulation Model
Urology 2017cited by 16position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Viraj A. Master · Emory University9 papers (2018–2023)Mehmet Asım Bilen · Emory Healthcare6 papers (2019–2023)Kenneth Ogan · Emory University6 papers (2019–2023)Milton Williams · University of Alabama at Birmingham5 papers (2021–2023)Dattatraya Patil · Emory University5 papers (2019–2023)Andrea Necchi · Second Foundation (United States)5 papers (2018–2025) · 4 papers (2024–2025)Hussein Sweiti · Janssen (Germany)4 papers (2024–2025)Michelle Higgins · Johns Hopkins University4 papers (2021–2023)Shreyas Joshi · Emory University3 papers (2021–2023)Évanguelos Xylinas · Université Claude Bernard Lyon 13 papers (2025–2025)Rohan Garje · Baptist Hospital of Miami3 papers (2024–2025)Aarti Sekhar · Emory University3 papers (2019–2022) · 3 papers (2024–2025)Stephen B. Williams · Cedars-Sinai Medical Center3 papers (2022–2025)Vikram M. Narayan · The University of Texas MD Anderson Cancer Center3 papers (2021–2023)Benjamin N. Schmeusser · Urology of Indiana3 papers (2022–2023)Hind Stitou · Institut Pasteur3 papers (2024–2025)Reza Nabavizadeh · Duke University3 papers (2021–2023)Neal D. Shore · Urologic Research Institute3 papers (2025–2025)